UBS is bullish on PTC Therapeutics, giving its stock a Buy rating as the company awaits a crucial FDA decision. This suggests analysts see potential upside, likely tied to optimism about the regulatory outcome.

Editor’s Note: For investors, this is a signal to watch—big bank endorsements often move markets, especially when paired with high-stakes FDA verdicts. If the decision goes PTC’s way, the stock could pop; if not, well… that’s the gamble with biotech. Either way, it’s a reminder of how Wall Street bets on regulatory roulette.

Analyst firm H.C. Wainwright is sticking with its "Buy" recommendation for Abeona Therapeutics, even after the FDA rejected one of the company's key treatments. The firm seems confident Abeona can bounce back, suggesting this setback might just be a temporary hurdle rather than a dealbreaker.

Editor’s Note: For investors watching Abeona, this is a signal that not all hope is lost. FDA rejections can tank biotech stocks, but when analysts keep the faith, it often means there’s a path forward—maybe revised data, better trials, or a different approach. If you’re into high-risk, high-reward plays, this kind of resilience could be worth keeping an eye on.